Biospace med Expands U.S. Market Penetration with ‘EOS’, which Cuts Radiation up to 90% vs. Conventional X-Rays

CAMBRIDGE, Mass. & PARIS--(EON: Enhanced Online News)--Biospace med announced today that it continues to penetrate the U.S. market with its FDA-cleared ‘EOS’ x-ray imager—the world’s first ultra-low-dose x-ray technology—recently adding new customers in the Midwest and Southeast regions of the United States. In addition, Professor Georges Charpak, inventor of the EOS technology, has received the ‘Centenary Medal’ from the French Radiological Society (SFR), the esteemed organization’s highest honor.

“In addition, because EOS uses significantly less radiation than a conventional x-ray or CT scan, it represents a remarkable advance in musculoskeletal imaging, as all other technologies deliver a substantial dose of radiation to the patient”

EOS can capture head-to-toe images of patients in a standing, weight-bearing position with a dramatic reduction in radiation dose—up to 10 times less than a conventional x-ray and up to 1000 times less than a CT (Computed Tomography) scan. Additionally, EOS images are designed to provide sharp detail and empower physicians to better diagnose and plan an effective course of treatment.

“We are very pleased to announce additional installations of our ultra-low-dose EOS x-ray imager in new markets across the United States,” said Marie Meynadier, Ph.D., chief executive officer of Biospace med. “Now that we have a beachhead in two new regions of the United States, we look forward to meeting the numerous healthcare institutions in these new markets that are still imaging patients with a conventional digital x-ray, as they are in the front rank of candidates to adopt EOS.

“In addition, because EOS uses significantly less radiation than a conventional x-ray or CT scan, it represents a remarkable advance in musculoskeletal imaging, as all other technologies deliver a substantial dose of radiation to the patient,” added Dr. Meynadier.

“Further, we are extremely proud that Professor Charpak has been recognized for his seminal contribution to low-dose x-ray imaging,” said Dr. Meynardier. “EOS is a major breakthrough in the safe and effective imaging of patients. Professor Charpak is most certainly deserving of the SFR’s highest award.”

About Professor Georges Charpak

Born in 1924 in Dabrovica, Poland, Charpak moved to France with his family in 1929. At the start of WW II, he joined the French Resistance. Arrested in 1943, Charpk was sent to Dachau concentration camp until its liberation in 1945. After his return to France, he embarked on a career in nuclear physics. Charpak received a Ph.D. in 1955 from the College de France, Paris, where he worked in the laboratory of Frédéric Joliot-Curie. In 1959 he joined the staff of European Laboratory for Particle Physics at CERN in Geneva and in 1984 also became the Joliot-Curie professor at the School of Advanced Studies in Physics and Chemistry, Paris. He was made a member of the French Academy of Science in 1985. Charpak received the Nobel Prize in physics in 1992 for his invention and development of particle detectors.

About Biospace med

Biospace med was founded on a unique partnership between Nobel Prize-winning physicist Georges Charpak, Ph.D., and a team of biomedical engineers, orthopedic surgeons and radiologists who have developed a complete orthopedic imaging solution. The Company’s lead product, EOS ultra-low-dose 2D/3D x-ray imager, allows full-body imaging of patients in a weight-bearing position that enables global assessment of balance and posture. EOS is a total solution in orthopedic imaging now available in the U.S. since receiving FDA 510(k) clearance. The Company has corporate headquarters in Cambridge, Mass., and Paris, as well as an office in Montreal, and is targeting a $2 billion orthopedic imaging marketplace. The Company’s U.S. headquarters is located at 185 Alewife Brook Parkway, #410, Cambridge, Mass. (toll free: +1-866-933-5301). Learn more at www.biospacemed.com.

View All Releases from This Organization